The Cox regression model was used to assess HR and 95% CI. For ORR, 95% CI was estimated using the Clopper-Pearson method; treatment difference was estimated using a stratified Cochran-Mantel-Haenszel ...

Michael Copley is a correspondent on NPR's Climate Desk. He covers what corporations are and are not doing in response to climate change, and how they're being impacted by rising temperatures.

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...

Mark Pearson joined WNEM as the Sports Director in May of 2023. Originally from Grand Rapids, Michigan, Mark loves being back in the mitten and closer to home. He previously spent four years at ...

Opzelura is a topical version of Incyte's oral drug Jakafi/Jakavi, which is FDA approved for myelofibrosis, polycythaemia vera and graft-versus-host-disease, and has been billed as a major growth ...

Incyte drug could be combined with immunotherapy One of the headlines trends this year is the wave of trials combining PD-1/PD-L1 inhibitors with a huge range of novel immunotherapy agents.